Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma.
Level 2 - randomized trial
Individual randomized controlled trial (Phase III)
PubMed 34818112 · doi:10.1200/JCO.21.02229
What was done
In the phase III CheckMate 067 trial, 945 treatment-naive patients with unresectable stage III or IV melanoma were randomly assigned 1:1:1 to receive nivolumab (1 mg/kg) plus ipilimumab (3 mg/kg) every 3 weeks for four doses followed by nivolumab (3 mg/kg) every 2 weeks (n = 314), nivolumab alone at 3 mg/kg every 2 weeks (n = 316), or ipilimumab alone at 3 mg/kg every 3 weeks for four doses (n = 315). Coprimary endpoints were progression-free survival and overall survival (OS) for each nivolumab-containing regimen versus ipilimumab alone. Secondary endpoints included objective response rate, safety, descriptive efficacy of combination versus nivolumab monotherapy, and melanoma-specific survival (MSS).
What was found
At a minimum follow-up of 6.5 years, median OS was 72.1 months with combination therapy, 36.9 months with nivolumab alone, and 19.9 months with ipilimumab. Median MSS was not reached in the combination group, 58.7 months with nivolumab, and 21.9 months with ipilimumab. For BRAF-mutant tumors, 6.5-year OS rates were 57% (combination), 43% (nivolumab), and 25% (ipilimumab); for BRAF-wild-type tumors, OS rates were 46%, 42%, and 22%, respectively. Among patients who discontinued treatment, the median treatment-free interval was 27.6 months for combination therapy, 2.3 months for nivolumab, and 1.9 months for ipilimumab. No new safety signals emerged since the 5-year analysis.
Why it matters
These findings establish long-term survival benchmarks in advanced melanoma, showing that dual checkpoint blockade produces durable survival exceeding 6 years in a substantial proportion of patients.
Limits
The trial was not statistically powered to formally compare nivolumab plus ipilimumab directly against nivolumab monotherapy (evaluations were descriptive). The abstract omits hazard ratios, confidence intervals, formal significance levels, and specific toxicity rates or severe adverse event numbers.
Cited by
- context Immune checkpoint blockade therapy leads to tumor disappearance in 50% of melanomas.